|
Trials Starting With "V" |
VA-HIT: Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol
-Trial Overview by Dr. MR Costanzo
VALIANT: Valsartan In Acute Myocardial Infarction Trial
-Trial Overview by Dr. Renzo Zanettini (2007)
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson’s Disease
-Trial Overview by Dr. Renzo Zanettini (2007)
VELOCITY: Evaluation of the Effect of Ultra-Short-Acting Clevidipine In the Treatment of Patients With Severe Hypertension
-Prolonged Infusion of Clevidipine Results in Safe and Predictable Blood Pressure Control in Patients with Acute Severe Hypertension by Dr. J. Varon (2004)
The VentrAssist U.S. Pivotal Bridge to Cardiac Transplantation Trial
-Trial Overview by Dr. Andrew J. Boyle (ACC 2009)
VERITAS: Value Of Endothelin Receptor Inhibition With Tezosentan In Acute Heart Failure Studies
-Trial Overview by Dr. John J. V. McMurray (ACC 2004)
Very Rapid Treatment of STEMI: Utilizing Pre-Hospital ECGs to Bypass the Emergency Department
-Trial Overview by Dr. Kenneth W. Baran (AHA 2010)
V-HEFT I: The Effects Of Vasodilator Therapy On Mortality In Chronic Congestive Heart Failure
V-HEFT II: Efficacy And Outcome With Felodipine In Heart Failure
-Trial Objectives (1991)
VISION: Vasodilator Induced Stress In Concordance with Adenosine
-Trial Overview by Dr. James E. Uldelson
Women's Health Study: Vitamin E in Primary Prevention
-Trial Overview by Dr. Julie E. Buring (ACC 2005)
Who Are We? Slide Downloading Policy Financial Disclosure We Do Not Promote Off Label Product Use Copyright Source of Slides Editorial Policy Links Policy Privacy Policy Access CME Programs
© 1999-2009 by Clinical Trial Results .org. None of the materials on this website may be reproduced, modified, distributed, transmitted, republished, displayed, or performed unless prior written approval is obtained by Clinical Trial Results. All such requests should be forwarded to Susan J. Marble at smarble@clinicaltrialresults.org. For further information please see the Policy section. Webmaster